PAM
RNAC icon

Panagora Asset Management’s Cartesian Therapeutics RNAC Stock Holding History

Panagora Asset Management’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-376
Closed -$14K – 1577
2022
Q1 		$14K Buy
+376
New +$23.5K ﹤0.01% 1513
2021
Q3 		– Sell
-48
Closed -$6K – 2266
2021
Q2 		$6K Sell
48
-36
-43% -$4.29K ﹤0.01% 2443
2021
Q1 		$11K Hold
84
– – ﹤0.01% 2389
2020
Q4 		$8K Buy
84
+52
+163% +$4.51K ﹤0.01% 2347
2020
Q3 		$2K Buy
+32
New +$2.45K ﹤0.01% 2598

Other funds holding RNAC

MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
N
NanoDimension Woodside, California $24.7M AUM 74.01% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Panagora Asset Management's RNAC Position: Q2 2022 in Review

Panagora Asset Management sold out of Cartesian Therapeutics (RNAC) in Q2 2022, closing a stake of 376 shares — an estimated $14K sold.

Panagora Asset Management first reported a position in RNAC in Q3 2020 and held it in 5 quarters. The position peaked at $14K in Q1 2022. 92 funds tracked by Wall St. Rank hold RNAC as of Q2 2022.

  • Panagora Asset Management reported no remaining Cartesian Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Panagora Asset Management sold 376 Cartesian Therapeutics shares in Q2 2022, an estimated $14K.
  • Panagora Asset Management first reported a position in Cartesian Therapeutics in Q3 2020 and held it in 5 quarters.
  • Panagora Asset Management's Cartesian Therapeutics position peaked at $14K in Q1 2022.
  • 92 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2022.

Based on Panagora Asset Management's 13F filing for Q2 2022, filed 15 Aug 2022.